Assertio Therapeutics (ASRT) stock price, revenue, and financials

Assertio Therapeutics market cap is $199 m, and annual revenue was $311.77 m in FY 2018

$199 M

ASRT Mkt cap, 10-Jun-2019

$57.2 M

Assertio Therapeutics Revenue Q2, 2019
Assertio Therapeutics Gross profit (Q2, 2019)55.1 M
Assertio Therapeutics Gross profit margin (Q2, 2019), %96.3%
Assertio Therapeutics Net income (Q2, 2019)-13.6 M
Assertio Therapeutics EBIT (Q2, 2019)3.6 M
Assertio Therapeutics Cash, 30-Jun-201968.3 M

Assertio Therapeutics Revenue

Assertio Therapeutics revenue was $311.77 m in FY, 2018

Embed Graph

Assertio Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

134.2m390.4m342.7m455.9m380.7m311.8m

Revenue growth, %

191%(12%)33%

Cost of goods sold

7.1m15.1m67.9m87.4m72.6m18.5m

Gross profit

127.1m375.2m274.8m368.5m308.1m293.3m

Gross profit Margin, %

95%96%80%81%81%94%

R&D expense

8.1m17.5m32.6m13.7m8.0m

General and administrative expense

199.4m204.5m195.7m119.2m

Operating expense total

124.9m393.1m431.4m422.9m268.1m

Depreciation and amortization

4.5m83.3m106.8m102.7m101.8m

EBIT

9.3m236.8m(50.4m)24.5m(42.2m)43.7m

EBIT margin, %

7%61%(15%)5%(11%)14%

Interest expense

911.0k9.3m73.4m83.7m73.6m68.9m

Interest income

662.0k599.0k485.0k681.0k1.2m

Pre tax profit

4.6m(123.2m)(64.5m)(103.9m)38.0m

Income tax expense

38.7m47.5m(24.2m)1.4m(1.1m)

Net Income

43.3m131.8m(75.7m)(88.7m)(102.5m)36.9m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

37.5m76.5m67.7m51.5m32.2m94.5m104.9m104.8m116.7m110.5m90.4m100.5m95.4m128.4m63.3m77.5m57.9m57.2m

Cost of goods sold

1.8m3.7m4.7m3.5m3.1m22.9m20.9m23.5m21.0m20.2m17.8m19.7m17.4m12.0m2.8m3.0m2.6m2.1m

Gross profit

35.7m72.8m63.1m48.0m29.1m71.6m83.9m81.2m95.7m90.3m72.7m80.7m78.0m116.4m60.5m74.5m55.4m55.1m

Gross profit Margin, %

95%95%93%93%90%76%80%78%82%82%80%80%82%91%96%96%96%96%

R&D expense

1.3m2.0m1.4m1.6m4.7m4.6m5.9m7.1m10.4m5.1m5.6m1.8m1.5m2.2m2.1m1.8m1.3m

General and administrative expense

26.4m32.5m32.6m27.1m57.4m49.1m52.6m51.9m51.6m48.5m50.0m48.9m29.0m31.3m33.4m25.0m24.8m

Operating expense total

30.6m40.8m41.2m34.8m42.1m111.7m101.6m109.1m107.0m109.3m97.1m104.5m94.2m77.1m67.5m67.9m54.9m53.6m

Depreciation and amortization

1.2m2.5m2.5m2.5m26.7m27.0m27.0m27.0m27.0m25.7m25.7m25.7m25.4m25.4m25.4m25.4m25.4m

EBIT

6.8m35.7m26.5m16.7m(9.8m)(17.2m)3.2m(4.3m)9.7m1.3m(6.7m)(4.1m)1.2m51.3m(4.2m)9.6m3.1m3.6m

EBIT margin, %

18%47%39%32%(31%)(18%)3%(4%)8%1%(7%)(4%)1%40%(7%)12%5%6%

Interest expense

626.0k616.0k1.9m6.0m22.1m22.7m20.1m20.3m20.1m17.8m17.8m18.1m17.0m17.2m16.6m14.8m

Interest income

27.0k27.0k20.0k23.0k61.0k62.0k130.0k67.0k113.0k250.0k282.0k72.0k229.0k67.0k677.0k

Pre tax profit

6.6m29.8m21.0m10.4m(16.2m)(18.9m)(26.5m)(26.9m)(16.5m)33.5m55.1m

Income tax expense

(66.0k)(4.0m)4.2m17.6m7.6m6.0m5.7m6.0m(202.0k)249.0k513.0k325.0k120.0k

Net Income

6.5m17.9m12.7m6.5m(11.6m)(21.7m)(11.8m)(20.9m)(10.5m)(12.9m)(26.7m)(26.7m)(16.0m)33.8m(21.0m)48.3m(14.3m)(13.6m)

Assertio Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

244.7m488.7m101.1m117.7m126.9m110.9m

Accounts Receivable

11.5m27.0m71.1m102.1m71.9m37.2m

Inventories

10.1m8.5m10.5m13.0m13.0m3.4m

Current Assets

337.0m617.6m309.0m306.2m230.9m208.1m

PP&E

8.3m7.1m14.8m15.5m13.0m13.1m

Total Assets

508.7m711.1m1.4b1.2b1.0b932.9m

Accounts Payable

41.8m12.8m14.9m14.7m6.1m

Short-term debt

Current Liabilities

156.9m57.5m219.6m227.2m310.6m246.0m

Long-term debt

Total Debt

Total Liabilities

712.5m

Additional Paid-in Capital

347.0k76.8m78.6m75.9m75.2m402.9m

Retained Earnings

(84.0m)(28.0m)(116.7m)(219.5m)(182.6m)

Total Equity

137.4m364.4m315.1m250.8m169.5m220.3m

Financial Leverage

3.7 x2 x4.3 x4.9 x6.1 x4.2 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

64.3m195.3m211.1m546.7m52.8m94.1m107.5m182.0m87.8m90.4m187.8m113.2m107.6m101.7m57.2m121.9m109.7m68.3m

Accounts Receivable

8.3m12.8m17.3m20.0m23.5m59.8m68.4m69.9m79.5m87.0m67.5m78.3m77.2m62.4m42.1m43.9m43.5m34.3m

Inventories

7.8m8.5m7.8m7.3m6.5m10.4m11.4m10.9m10.4m11.3m12.0m10.4m10.4m5.4m5.0m4.3m3.1m3.0m

Current Assets

110.6m313.3m309.6m632.5m613.5m232.2m302.8m292.6m230.2m260.9m286.8m219.0m219.3m193.3m127.1m227.4m182.0m139.0m

PP&E

8.4m8.1m7.7m7.4m7.2m16.0m15.4m15.1m16.2m16.1m15.1m14.5m13.9m11.7m11.1m11.8m16.6m13.1m

Total Assets

156.7m468.7m458.5m742.4m704.4m1.3b1.4b1.3b1.2b1.2b1.2b1.1b1.1b1.0b912.2m983.5m883.5m812.9m

Accounts Payable

30.3m39.5m44.3m45.6m55.8m113.9m3.2m7.4m11.3m18.5m7.2m12.4m7.0m10.2m3.1m17.4m5.4m2.2m

Current Liabilities

34.1m119.3m114.6m116.0m61.7m135.7m180.2m309.1m217.9m216.0m301.5m278.9m263.2m257.1m231.8m261.1m223.0m176.9m

Total Liabilities

721.0m741.1m674.9m615.4m

Common Stock

246.0m252.6m258.2m269.9m277.9m283.9m298.1m306.1m309.4m316.7m323.0m6.0k6.0k6.0k

Additional Paid-in Capital

1.1m1.9m75.5m78.0m79.1m80.8m78.8m78.7m79.2m75.9m75.7m75.7m75.1m74.9m400.9m405.4m407.9m

Retained Earnings

(125.8m)(66.1m)(53.4m)(46.9m)36.1m14.4m2.6m(48.9m)(59.5m)(72.4m)(143.8m)(170.4m)(186.4m)(185.7m)(206.7m)(158.5m)(196.9m)(210.5m)

Total Equity

92.2m160.3m179.3m263.5m360.1m346.1m341.7m299.7m297.1m290.7m230.2m211.4m198.6m206.1m191.2m242.4m208.5m197.4m

Financial Leverage

1.7 x2.9 x2.6 x2.8 x2 x3.8 x4 x4.5 x4.2 x4.3 x5.1 x5.1 x5.3 x4.9 x4.8 x4.1 x4.2 x4.1 x

Assertio Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

43.3m131.8m(75.7m)(88.7m)(102.5m)36.9m

Depreciation and Amortization

6.2m12.0m85.7m109.4m105.5m106.4m

Accounts Receivable

(7.8m)(15.0m)(44.1m)(30.9m)30.1m35.3m

Inventories

4.3m1.7m9.3m(3.7m)(1.9m)9.0m

Accounts Payable

16.0m(2.7m)(2.7m)(1.6m)

Cash From Operating Activities

9.8m(55.9m)143.9m65.5m62.2m72.5m

Purchases of PP&E

(1.8m)(599.0k)(1.7m)(2.9m)(666.0k)(5.5m)

Cash From Investing Activities

(38.0m)(47.3m)(1.1b)45.5m

Cash From Financing Activities

243.9m347.2m576.6m(94.4m)(81.3m)

Interest Paid

39.5m71.1m55.5m48.4m

Income Taxes Paid

45.0k

Assertio Therapeutics Ratios

USDY, 2019

Financial Leverage

4.1 x